Literature DB >> 34974317

Analysis of sodium 2-mercaptoethane sulfonate in rat plasma using high performance liquid chromatography tandem-mass spectrometry.

Abigail B Donkor1, Carl W White2, Heidi J Nick2, Brian A Logue3.   

Abstract

Sodium 2-mercaptoethane sulfonate (MESNA) is a thiol-containing compound that has proven to be effective in inactivating acrolein, the toxic metabolite of some anti-cancer drugs (e.g., cyclophosphamide and ifosphamide). Also, it scavenges free radicals which cause numerous disorders by attacking biological molecules. Current methods available to analyze MESNA in biological matrices include colorimetry and high-performance liquid chromatography (HPLC) with ultraviolet, fluorescence, or electrochemical detection. These methods have several limitations including low sensitivity, poor selectivity, a high degree of difficulty, and long analysis times. Hence, a rapid, simple, and sensitive HPLC tandem mass spectrometry (MS/MS) method was developed and validated to quantify MESNA in rat plasma following IP administration. The analysis of MESNA was accomplished via plasma protein precipitation, centrifugation, supernatant evaporation, reconstitution, and HPLC-MS/MS analysis. The method showcases an outstanding limit of detection (20 nM), excellent linearity (R2 = 0.999, and percent residual accuracy >90%) and a wide linear range (0.05-200 μM). The method also produced good accuracy and precision (100 ± 10% and <10% relative standard deviation, respectively). The validated method was successfully used to analyze MESNA from treated animals and will allow easier development of MESNA for therapeutic purposes.
Copyright © 2021 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Antineoplastic; Chemoprotectant; Free radical; LC-MS/MS; Method development

Mesh:

Substances:

Year:  2021        PMID: 34974317      PMCID: PMC8792353          DOI: 10.1016/j.jchromb.2021.123088

Source DB:  PubMed          Journal:  J Chromatogr B Analyt Technol Biomed Life Sci        ISSN: 1570-0232            Impact factor:   3.205


  27 in total

1.  Bioanalytical method validation--a revisit with a decade of progress.

Authors:  V P Shah; K K Midha; J W Findlay; H M Hill; J D Hulse; I J McGilveray; G McKay; K J Miller; R N Patnaik; M L Powell; A Tonelli; C T Viswanathan; A Yacobi
Journal:  Pharm Res       Date:  2000-12       Impact factor: 4.200

2.  Validation of high-performance liquid chromatography methods for pharmaceutical analysis. Understanding the differences and similarities between validation requirements of the US Food and Drug Administration, the US Pharmacopeia and the International Conference on Harmonization.

Authors:  Ghulam A Shabir
Journal:  J Chromatogr A       Date:  2003-02-14       Impact factor: 4.759

3.  Tissue sulfhydryl groups.

Authors:  G L ELLMAN
Journal:  Arch Biochem Biophys       Date:  1959-05       Impact factor: 4.013

4.  Protective effects of MESNA (2-mercaptoethane sulphonate) against acetaminophen-induced hepatorenal oxidative damage in mice.

Authors:  Göksel Sener; Ozer Sehirli; Sule Cetinel; Berrak G Yeğen; Nursal Gedik; Gül Ayanoğlu-Dülger
Journal:  J Appl Toxicol       Date:  2005 Jan-Feb       Impact factor: 3.446

5.  Pharmacokinetics of mesna and dimesna after simultaneous intravenous bolus and infusion administration in patients undergoing bone marrow transplantation.

Authors:  A el-Yazigi; P Ernst; S al-Rawithi; E Legayada; D A Raines
Journal:  J Clin Pharmacol       Date:  1997-07       Impact factor: 3.126

6.  Simultaneous determination of BNP7787 and its metabolite mesna in plasma and tissue by micro-HPLC with a dual electrochemical detector.

Authors:  Miranda Verschraagen; T H Ursula Zwiers; Emine Torun; Martin G Donker; Nico J Reinhoud; Wim J F Van der Vijgh
Journal:  J Pharm Sci       Date:  2003-05       Impact factor: 3.534

7.  Pharmacokinetics of intravenous and oral sodium 2-mercaptoethane sulphonate (mesna) in normal subjects.

Authors:  C A James; T G Mant; H J Rogers
Journal:  Br J Clin Pharmacol       Date:  1987-05       Impact factor: 4.335

Review 8.  Determination of endogenous thiols and thiol drugs in urine by HPLC with ultraviolet detection.

Authors:  Krzysztof Kuśmierek; Grazyna Chwatko; Rafał Głowacki; Edward Bald
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2009-03-31       Impact factor: 3.205

9.  Clinical overview of mesna.

Authors:  H Burkert
Journal:  Cancer Treat Rev       Date:  1983-09       Impact factor: 12.111

10.  The anti-tumour activity of ifosfamide on heterotransplanted testicular cancer cell lines remains unaltered by the uroprotector mesna.

Authors:  C Bokemeyer; H J Schmoll; E Ludwig; A Harstrick; T Dunn; J Casper
Journal:  Br J Cancer       Date:  1994-05       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.